NCT03291288View on ClinicalTrials.gov

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 26, 2018

Primary Completion Date

September 26, 2018

Study Completion Date

April 16, 2021

Conditions
Drug Interaction Potential
Interventions
DRUG

Tolbutamide

Commercially available tolbutamide

DRUG

Midazolam

Commercially available midazolam

DRUG

Pexidartinib

Pexidartinib is formulated as opaque, white, 200-mg capsules

Trial Locations (11)

8011

Christchurch Hospital NZ, Christchurch

10002

National Taiwan University Hospital, Taipei

10042

Northwell Health, Lake Success

48201

Karmanos Cancer Center, Detroit

66205

University of Kansas Cancer Center, Westwood

75230

Mary Crowley Cancer Research, Dallas

85258

HonorHealth, Scottsdale

85719

University of Arizona, Tucson

94304

Stanford University, Palo Alto

02215

Dana-Farber Cancer Institute, Boston

2333 ZA

Leids Universitair Medisch Centrum, Leiden

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT03291288 - Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics) | Biotech Hunter | Biotech Hunter